腾讯电竞

"We Envision Growth Strategies Most Suited
to Your Business"

Glaucoma Therapeutics Market to Reach $11.05 Billion by 2027; Rising Prevalence of Glaucoma amongst Geriatric Population to Aid Growth

September 09, 2020 | Healthcare

The global glaucoma therapeutics market size is projected to reach USD 11.05 billion by 2027. The rising cases of glaucoma, especially among the aging population because of the surging screen time of laptops & smartphones would affect growth positively. This information is given by Fortune Business Insights™ in a new report, titled, “Glaucoma Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Beta Blockers, Prostaglandins Analogs, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, Combination Drugs, and Others), By Disease Indication (Open Angle Glaucoma, Angle Closure Glaucoma, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027.” The report further mentions that the market stood at USD 6.59 billion in 2019. However, it is set to exhibit a CAGR of 6.1% during the forecast period between 2020 to 2027.


AbbVie Completes Acquisition of Allergan to Expand its Leading Position


In May 2020, AbbVie Inc., a biopharmaceutical company headquartered in the U.S. declared the completion of acquisition of Allergan, a pharmaceutical company based in Ireland. The recent transaction would diversify and broaden the former’s revenue base. At the same time, it would complement its existing leading position in the market. Besides, it would provide immediate and scale AbbVie's growth platform.


To get a detailed report summary and research scope of this market, click here:


http://www.hqskjy.com/industry-reports/glaucoma-therapeutics-market-100312


Increasing Number of Pipeline Products under Development to Spur Growth


As of 2020, the clinicaltrials.gov website shows that at present, around 70 ongoing studies associated with glaucoma therapeutics exist. It proves that there are similar other pipeline products for the treatment of this condition that are currently under the development stage. Apart from that, the emergence of the COVID-19 pandemic has raised the demand for glaucoma therapeutics across the globe as several government healthcare facilities have postponed all the surgeries related to this condition. Hence, people are on a rat race to stock up medications to delay the progression of glaucoma.


However, several regulatory recall cases of such products are generating fear and skepticism among the patient and healthcare professionals. This factor may hamper the glaucoma therapeutics market growth in the forthcoming years.


Key Players Engage in Acquisitions & Collaborations to Gain Competitive Edge


The market consists of several companies. Out of those, Allergan and Novartis AG are in the dominant positions. They are growing rapidly owing to their engagement in mergers and partnerships, as well as new product developments. Some of the other players are focusing on the distribution and manufacturing of glaucoma therapeutics products to gain a competitive edge.


Fortune Business Insights™ lists out the names of all the reputed glaucoma therapeutics providers operating in the global market. They are as follows:



  • Merck & Co., Inc. (U.S.)

  • Novartis AG (Switzerland)

  • Allergan plc (part of AbbVie Inc.) (Ireland)

  • Bausch and Lomb Incorporated (U.S.)

  • Teva Pharmaceuticals Industry (Israel)

  • Pfizer, Inc. (U.S.)

  • Aerie Pharmaceuticals (U.S.)

  • Inotek Pharmaceuticals (U.S.)

  • Other Prominent Players


A Notable Industry Development-



  • December 2019: Senju Pharmaceutical Co., Ltd. unveiled a new, reliable treatment option for ocular hypertension and glaucoma in Japan. It is called AIBETA® Combination Ophthalmic Solution. It would help in lowering the intraocular pressure. The company is looking forward to enhancing the adherence of glaucoma patients.


Further Report Findings-



  • Geographically, North America procured USD 2518.31 million in 2019 in terms of revenue and is likely to lead throughout the forthcoming years. This growth is attributable to the presence of an efficient treatment framework, as well as a well-established hospital infrastructure for the diagnosis of this condition in this region.

  • Asia Pacific is anticipated to exhibit the highest growth on account of the increasing aging population in Japan and China.

  • Based on product type, the prostaglandins analogs segment generated 40.3% in terms of market share in 2019. It would grow significantly because of its ability to reduce intraocular pressure (IOP) efficiently and its possession of lesser side effects, unlike the other glaucoma therapeutics.


The global market can be segmented in the following way:











































 ATTRIBUTE



  DETAILS



Study Period



  2016-2027



Base Year



  2019



Forecast Period



  2020-2027



Historical Period



  2016-2018



Unit



  Value (USD Billion)



Segmentation



By Drug Class



  • Beta Blockers

  • Prostaglandins Analogs


    • Latanoprost

    • Bimatoprost

    • Travoprost

    • Others


  • Alpha Adrenergic Agonists

  • Carbonic Anhydrase Inhibitors

  • Combination Drugs

  • Others



By Disease Indication



  • Open Angle Glaucoma

  • Angle Closure Glaucoma

  • Others



By Distribution Channel



  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy



By Geography



  • North America (U.S and Canada)

  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

  • Asia-Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia- Pacific)

  • Latin America (Brazil, Mexico, and Rest of Latin America)

  • Middle East and Africa (GCC countries, South Africa, and Rest of the Middle East and Africa)


Glaucoma Therapeutics Market
  • PDF
  • 2019
  • 2016-2018
  • 125

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Our Clients

Samsung
baxter
Daewoo_logo
kpmg
parker-hannifin
bridgestone-26989
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X
海南4+1 bbin体育 天天斗牛 公益福彩app 360直播吧